Cytokinetics (NASDAQ: CYTK) announced its second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) scheduled for May 30th, 2025, at the Mission Bay Conference Center in San Francisco.

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025.Late Breaking Science PresentationsTitle: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild SymptomsPresenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, ItalyDate: May 17, 2025Topic: Chronic Heart FailureSession Title: Late Breaking Science in Heart Failure, Cardiomyopathies, Pulmonary Hypertension and Valvular Heart DiseaseSession Type: Late Breaking ScienceSession Time: 4:00 - 5:00 PM CESTPresentation Time: 4:20 PM CESTLocation: Room 1Title: SEQUOIA-HCM: Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical RegionPresenter: Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of GlasgowDate: May 18, 2025Topic: Chronic Heart FailureSession Title: Hottest Trials and Trial Updates (2)Session Type: Late Breaking ScienceSession Time: 10:45 AM - 12:15 PM CESTPresentation Time: 11:11 AM CESTLocation: Room 1Title: The Effect of Omecamtiv Mecarbil on Outcomes Analyzed Using the Win Ratio: An Exploratory Analysis of GALACTIC-HFPresenter: Kieran F. Docherty, Ph.D., Clinical Senior Lecturer in Heart Failure and Clinical Trials and Honorary Consultant Cardiologist, University of GlasgowDate: May 19, 2025Topic: PharmacotherapySession Title: Clinical Trials Updates in Medical TherapySession Type: Late Breaking ScienceSession Time: 1:45 PM - 2:45 PM CESTPresentation Time: 2:25 PM CESTLocation: Room 1ePoster PresentationTitle: Associations Between Age and Sex and Cardiovascular Outcomes in Patients with Non-Obstructive Hypertrophic CardiomyopathyPresenter: Paulos Gebrehiwet, Ph.D., M.S., Senior Manager, Health Economics and Outcomes Research, CytokineticsDate: May 17, 2025Topic: ClinicalSession Title: ePosters in Myocardial Disease (2)Session Type: ePostersSession Time: 9:00 AM - 5:00 PM CESTPresentation Time: 1:26 PM CESTLocation: ePosters Screen 14 - Research GatewayAbout CytokineticsCytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.Forward-Looking StatementsThis press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements